Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948872 | 0.90 | MEN1 (0.45) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL12557317 | 0.90 | MEN1 (0.45) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL24737159 | 0.90 | MEN1 (0.45) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL14681085 | 0.85 | STAT3 (0.42) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL17368652 | 0.85 | STAT3 (0.42) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL13166654 | 0.83 | SYNJ2 (0.51) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL12556577 | 0.83 | STAT3 (0.46) | STAT3LGALS8LGALS3LGALS4 | |
| SCHEMBL12557233 | 0.83 | STAT3 (0.46) | STAT3LGALS8LGALS3LGALS4 | |
| SCHEMBL17368667 | 0.83 | STAT3 (0.41) | STAT3MEN1KMT2AGJA1GJB2 | |
| SCHEMBL10905061 | 0.81 | AMY1A (0.57) | STAT3MEN1KMT2AGJA1GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102154417-A | Method for preparing periplocymarin | UNIV TIANJIN TRADITIONAL CHINESE MEDICINE | 2011-08-17 | — | — | CN | disclosed |
| EP-1605950-A4 | NOVEL CHEMICAL ENTITIES AND METHODS FOR THEIR USE IN TREATMENT OF METABOLIC DISORDERS | ACCERA INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060189545-A1 | Novel chemical entities and methods for their use in treatment of metabolic disorders | ACCERA, INC. | 2006-08-24 | — | — | US | disclosed |
| CN-1756554-A | Novel chemical entities and methods for their use in the treatment of metabolic disorders | ACCERA INC (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1605950-A2 | NOVEL CHEMICAL ENTITIES AND METHODS FOR THEIR USE IN TREATMENT OF METABOLIC DISORDERS | Accera, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004077938-A2 | NOVEL CHEMICAL ENTITIES AND METHODS FOR THEIR USE IN TREATMENT OF METABOLIC DISORDERS | ACCERA INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189545-A1 | Novel chemical entities and methods for their use in treatment of metabolic disorders | BACE1, PC, PSEN2 | STAT3 4804/4885MEN1 1409/4885KMT2A 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.